Goldman Sachs
ABUS icon

Goldman Sachs’s Arbutus Biopharma ABUS Stock Holding History

Goldman Sachs’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-34,200
Closed -$723K – 7094
2014
Q3 		$723K Buy
+34,200
New +$558K ﹤0.01% 4942

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs's ABUS Position: Q2 2026 in Review

Goldman Sachs increased its Arbutus Biopharma (ABUS) stake by 219% in Q2 2026, buying an estimated $10.6M and bringing the position to 3,506,802 shares worth $16.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2811.

Goldman Sachs first reported a position in ABUS in Q4 2013 and has held it in 49 quarters since. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Goldman Sachs held 3,506,802 shares of Arbutus Biopharma worth $16.8M as of Q2 2026.
  • Goldman Sachs bought 2,406,368 Arbutus Biopharma shares in Q2 2026, an estimated $10.6M.
  • Arbutus Biopharma made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2811 holding.
  • Goldman Sachs first reported a position in Arbutus Biopharma in Q4 2013 and has held it in 49 quarters since.
  • 176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.